EU Pharma Revision Proposals Still Awaiting Start Of Legislative Debate
Executive Summary
The texts of the proposals cannot be formally presented to the European Parliament until they have been translated into all of the EU’s official languages.
You may also be interested in...
Lawmakers Finally Kick Off Debate On EU Pharma Overhaul
The late delivery of the “pharmaceutical package” leaves little time for the legislative process to take shape before European Parliament elections are held in June next year.
EU Pharmaceutical Reform: A Delicate Negotiation
The European Commission may well be flexible over its proposals on data protection periods, but it is unlikely to give ground on plans to restructure the European Medicines Agency and to introduce a new temporary emergency marketing authorization, says lawyer Vincenzo Salvatore.
EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes
Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.